BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30
• 31

• Press Releases

  Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

  July 2, 2026

   · 

  4 min read
• Press Releases

  Brenus Pharma Strengthens Its Governance With Designation of a New President and Appointment of Former Novo Nordisk EVP as Independent Member

  July 2, 2026

   · 

  1 min read
• Press Releases

  Xeltis exceeds 50% enrollment in US Pivotal trial for aXess™, its vascular access device for hemodialysis

  July 2, 2026

   · 

  4 min read
• Press Releases

  Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

  July 2, 2026

   · 

  4 min read
• Press Releases

  Anaveon Appoints Laetitia Pouzol as Chief Scientific Officer

  July 2, 2026

   · 

  3 min read
• Press Releases

  HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification

  July 2, 2026

   · 

  8 min read
• Press Releases

  Alligator Announces First Patient Dosed in Investigator-Initiated Study of Intratumoral Mitazalimab in Early-Stage Breast Cancer

  July 2, 2026

   · 

  3 min read
• Press Releases

  Besins Healthcare Strengthens Innovation Capabilities with Acquisition of UniD Manufacturing, a Specialist in Long-Acting Drug Delivery Technologies

  July 2, 2026

   · 

  3 min read
• Press Releases

  Genoskin Doubles US Foothold to Launch Local Primary HumanMast Cell Production for North American Customers

  New 8,000-square-foot Laboratory and Office Facility in Salem, Massachusetts, will Provide Local Primary Human Mast Cell Production Capabilities to Address Increasing US Demand and Offer Faster Access to North American Researchers

  July 2, 2026

   · 

  1 min read
• 

  Approvals

  Vertex’s Casgevy becomes first approved gene therapy for young kids with rare blood disorders

  The FDA approved the expansion of Casgevy, which had previously been greenlit for patients 12 and up, into a younger pediatric population under the agency’s Commissioner’s National Priority Voucher program.

  July 2, 2026

   · 

  2 min read

   · 

  Tristan Manalac